Search clinical trials for: BMS-927711 (CGRP Antagonist)

Total 402 results

Pfizer

Completed

Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition

Migraine

United States
Assiut University

Not yet recruiting

Role of Novel Biomarkers Associated With In-stent Restenosis After Percutaneous Coronary Intervention

In-stent Restenosis
Bristol-Myers Squibb

Completed

A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer

Prostate Cancer

United States
Bristol-Myers Squibb

Completed

Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020

Immunosuppression For Disease
Bristol-Myers Squibb

Completed

Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance

Type 2 Diabetes

Russian Federation
Bristol-Myers Squibb

Completed

A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets

Lupus

United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants

Healthy Volunteers

Netherlands
PRAECIS Pharmaceuticals Inc.

Suspended

The Plenaxis® Experience Study

Prostate Cancer

United States
Bristol-Myers Squibb

Completed

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

Healthy Participants

United States
National Cancer Institute (NCI)

Completed

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

Healthy Volunteers

United Kingdom
Bristol-Myers Squibb

Terminated

Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers

Atrial Fibrillation

Canada, United States
AstraZeneca

Completed

Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)

Type 2 Diabetes Mellitus
Bristol-Myers Squibb

Completed

Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole

Alzheimer Disease

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants (CheckMate 6DW)

Mesothelioma, Malignant

China
Bristol-Myers Squibb

Completed

A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Healthy Participants

United States
A.O. Ospedale Papa Giovanni XXIII
Boston Scientific Corporation; Medtronic Vascular; Case Western Reserve University

Unknown

Optical Coherence Tomography for Drug Eluting Stent Safety (ODESSA)

Coronary Artery Disease

Italy
National Cancer Institute (NCI)

Active, not recruiting

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Chronic Myeloid Leukemia, BCR-ABL1 Positive

United States, Canada
Celgene

Recruiting

A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Israel, Spain, Denmark, France, Germany, Netherlands
Bristol-Myers Squibb

Completed

Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)

Mesothelioma

Brazil, United States, China, Italy, Australia, Belgium, Chile, Colombia, France, Germany, Greece, Japan, Mexico, Netherlands, Poland, Romania, Russian Federation, South Africa, Switzerland, Turkey, United Kingdom
Bristol-Myers Squibb
Mayo Clinic

Terminated

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Breast Cancer

United States
Bristol-Myers Squibb

Completed

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

Healthy Volunteers

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) (CheckMate 650)

Prostate Cancer

Canada, Poland, United States, Australia, Austria, Denmark, France, Germany, Italy, Spain
AstraZeneca

Completed

Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants

Type 2 Diabetes Mellitus

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy (CheckMate722)

Non-Small-Cell Lung Carcinoma

United States, China, Taiwan, Spain, Korea, Republic of, France, Canada, Hong Kong, Japan, Singapore
Bristol-Myers Squibb

Recruiting

A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

Healthy Volunteers

United Kingdom
Bristol-Myers Squibb

Completed

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

Breast Cancer

United States, Peru, Argentina, Mexico
M.D. Anderson Cancer Center
Bristol-Myers Squibb; Merck Sharp & Dohme LLC; Commonwealth Foundation for Cancer...

Terminated

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Breast Cancer

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Canada, United States, Spain, France, Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Minimal Residual Disease | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission

United States
Bristol-Myers Squibb

Recruiting

A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors

Advanced Cancer

United States, Spain, Belgium, Argentina, Korea, Republic of, Japan
Bristol-Myers Squibb
US Oncology Research

Completed

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Metastatic Breast Cancer

United States
Bristol-Myers Squibb
PRA Health Sciences

Completed

Effect of BMS-914392 on Pharmacokinetics of Metoprolol

Atrial Fibrillation

United States
Sandoz

Completed

To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets

Allergy
Bristol-Myers Squibb

Recruiting

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

NSCLC

United States, Argentina, Chile, France, Italy, Poland, Romania, Spain
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes

Type 2 Diabetes

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

Breast Cancer

Czech Republic, United States, Spain, United Kingdom, Ireland, Poland, France, Sweden
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Norway, United States, Spain, United Kingdom, Canada
Celgene

Not yet recruiting

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE)

Multiple Myeloma

China, Australia, United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers

Healthy Participants

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Minimal Residual Disease | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Dwight Owen
National Cancer Institute (NCI)

Recruiting

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Montefiore Medical Center
National Institute on Drug Abuse (NIDA)

Completed

Buprenorphine Group Medical Visits in Primary Care (G-BMT)

Opioid-Related Disorders

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

Healthy Participants

United States
VA Office of Research and Development

Completed

Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty (DIVA)

Saphenous Vein Graft Atherosclerosis

United States
Bristol-Myers Squibb
Janssen, LP

Active, not recruiting

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Multiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin's Lymphoma

United States, Poland, Italy, Belgium, France, Greece
CSL Behring

Completed

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Rheumatoid Arthritis

Italy, Japan, Taiwan, United States, Spain, Argentina, Belgium, Germany, Korea, Republic of, Czechia, Russian Federation, France, Mexico, Poland, South Africa, Hungary, Brazil, Canada, Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ipilimumab and Imatinib Mesylate in Advanced Cancer

Metastatic Melanoma | Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Melanoma | C-KIT Tyrosine Kinase Protein Overexpression | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Gastrointestinal Stromal Tumor | Pathologic Stage IV Cutaneous Melanoma... and other conditions

United States

Search clinical trials for: BMS-927711 (CGRP Antagonist)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations